Zymergen IPO

zymergen.com/BioTechFounded: 2013Funding to Date: $920.06MM

Zymergen was founded in 2013 by Jed Dean, Joshua Hoffman, and Zach Serber. The company has not officially endorsed a plan to participate in an IPO.

Zymergen is a science and material innovation company that develops and commercializes novel materials with a unique technology platform that combines biology, machine learning and automation. The company has raised nearly $900 million in Venture Capital funding from investors including Baillie Gifford, Baron Funds, Innovation Endeavors, Mission Bay Capital, Data Collective, Codon Capital, Two Sigma Investments, True Ventures, Threshold Ventures, Obvious Ventures, SoftBank Investment Advisers, Two Sigma Ventures, and Tao Capital Partners. Per company press releases, Zymergen last raised $300 million in September 2020 at a post-money valuation of approximately $1.75 billion.

Register for Details

For more details on financing and valuation for Zymergen, register or login.

Please provide your first name.
Please provide your last name.
Please provide a valid email address.

Already registered? Click here to log in

Valuation

Date of Last Funding Round

Sep 2020

Amount Last Raised

$1.75 B

Value at Last Round

$300 MM

Total Funding to Date

$920.0 MM

Enterprise Value (based on primary financings)